Results 101 to 110 of about 5,752,243 (395)

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. [PDF]

, 2016
Conventional cytogenetics and interphase fluorescence in situ hybridization (FISH) identify high-risk multiple myeloma (HRM) populations characterized by poor outcomes.
Amer Beitinjaneh, Amrita Krishnan, Anita D'Souza, Attal, Avet-Loiseau, Avet-Loiseau, Avet-Loiseau, Baldeep Wirk, Bipin N. Savani, Boyd, Boyd, Chang, Chng, Chng, Cindy Lee, Cristina Gasparetto, Dan Vogl, David Vesole, Emma C. Scott, Fonseca, Fonseca, Fonseca, Gerhard Hildebrandt, Hanamura, Hari, Harousseau, Hebraud, Henry Fung, Hillard Lazarus, Jason Tay, Jean Yared, Jennifer Le-Rademacher, Jiaxing Huang, Joseph Mikhael, Kapoor, Kenneth Meehan, Leona Holmberg, Manish Sharma, Matt Kalaycio, Muneer Abidi, Munshi, Muthalagu Ramanathan, Neben, Nooka, Palumbo, Parameswaran Hari, Richard T. Maziarz, Robert Kyle, Saad Usmani, Shaji Kumar, Shaughnessy, Siddhartha Ganguly, Sonneveld, Taiga Nishihori, Tomer Mark, Usmani, Yago Nieto   +56 more
core   +2 more sources

Inhibiting FAT1 Blocks Metabolic Bypass to Enhance Antitumor Efficacy of TCA Cycle Inhibition through Suppressing CPT1A‐Dependent Fatty Acid Oxidation

Advanced Science, EarlyView.
This study demonstrates that mutant FAT1 promotes ASCL2‐driven, CPT1A‐dependent fatty acid oxidation, leading to resistance to CPI‐613‐mediated TCA cycle inhibition in head and neck cancer. In vivo gene depletion of mutant FAT1 with LNP‐sgFAT1 suppresses tumor growth and restores CPI‐613 sensitivity, revealing a targetable metabolic bypass with ...
Fanghui Chen, Jianqiang Yang, David O. Popoola, Fan Yang, Yajie Liu, Dongsheng Wang, Zhaohui S. Qin, Zhengjia Chen, Nabil F. Saba, Zhuo G. Chen, Yamin Li, Yong Teng   +11 more
wiley   +1 more source

Dissecting racial disparities in multiple myeloma

Blood Cancer Journal, 2020
Multiple myeloma (MM) is a fatal plasma cell dyscrasia with a median overall survival of 5 to 10 years. MM progresses from the more common but often subclinical precursor states of monoclonal gammopathy of undetermined significance (MGUS), and smoldering
Catherine R. Marinac, I. Ghobrial, B. Birmann, J. Soiffer, T. Rebbeck   +4 more
semanticscholar   +1 more source

An unusual case of multiple myeloma [PDF]

, 2013
The case concerns the unusual presentation of a non-secretory multiple myeloma with diarrhoea secondary to large bowel infiltration. In December 2009, a 74-year-old lady presented to hospital and complained of a two year history of intermittent ...
Delicata, Julian, Farrugia, Daniel
core  

Combining PIM‐2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding

Advanced Science, EarlyView.
The findings suggest that the combination of PIM‐2 and PARP1 inhibitors can induce MICA expression on MM cells, thereby activating NK cells through NKG2D binding. This process may restore NK cell function and serve as a potential therapeutic approach for MM patients. Abstract While immunogenic death in tumor cells activates specific anti‐tumor T cells,
Zhaoyun Liu, Wenhui Lei, Xiaohan Liu, Hui Liu, Kai Ding, Jia Song, Rong Fu   +6 more
wiley   +1 more source

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma

HemaSphere
The 2/20/20 International Myeloma Working Group (IMWG) score is the most employed risk score in clinical practice to evaluate the risk of progression from smoldering multiple myeloma (SMM) to symptomatic multiple myeloma.
Anna deDaniel, Luis Gerardo Rodríguez‐Lobato, Natalia Tovar, M. Teresa Cibeira, David F. Moreno, Aina Oliver‐Caldés, Ignacio Isola, Ester Lozano, Joan Bladé, Laura Rosiñol, Carlos Fernández de Larrea   +10 more
doaj   +1 more source

A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma

Molecular Cancer Therapeutics, 2020
Multiple myeloma is a plasma cell malignancy, which grows in the bone marrow (BM). The major population of cells in the BM is represented by neutrophils and they can form neutrophil extracellular traps (NET).
Marina Li, Cindy Lin, Hui Deng, J. Strnad, L. Bernabei, D. Vogl, James J. Burke, Yulia Nefedova   +7 more
semanticscholar   +1 more source

Multiple myeloma bone disease: from mechanisms to next generation therapy [PDF]

, 2017
Multiple myeloma bone disease is a major cause of morbidity and mortality in multiple myeloma patients and persists even in patients in remission. Multiple myeloma bone disease is caused by an uncoupling of bone remodelling, with increased osteoclast ...
BARON, Frédéric, BEGUIN, Yves, CAERS, Jo, Heusschen, Roy, Muller, Joséphine, WITHOFS, Nadia   +5 more
core  

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells [PDF]

, 2017
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells in the bone marrow (BM). Recently, several studies have highlighted the role of pathogens in either promoting or dampening malignancies of unrelated origin.
Bertrand, Mathieu, De Beule, Nathan, De Bruyne, Elke, De Trez, Carl, De Veirman, Kim, Favreau, Mérédis, Maes, Ken, Magez, Stefan, Menu, Eline, Radwanska, Magdalena, Samali, Afshin, Vanderkerken, Karin   +11 more
core   +3 more sources

LncDARS‐AS1 Regulates ATP1A1 Stability and Enhances Na+/K+ ATPase Activity to Promote Osteosarcoma Metastasis

Advanced Science, EarlyView.
This study identifies LncDARS‐AS1 as a novel oncogenic regulator that stabilizes ATP1A1 and enhances Na⁺/K⁺ ATPase activity, promoting osteosarcoma metastasis. Targeting the LncDARS‐AS1/ATP1A1/NKA axis, including pharmacological inhibition with digoxin, offers promising opportunities for the development of new therapeutic strategies against ...
Mingxian Xu, Jiatian Wei, Xiaoyu Feng, Qinkai Zhang, Jian Chen, Xinyue Wang, Xiudan Zhan, Bing Lu, Weitang Guo, Mingzhe Cheng, Renxuan Huang, Shao Xu, Changye Zou   +12 more
wiley   +1 more source